



or a pharmaceutically acceptable salt thereof.

7. A method according to claim 1, wherein the compound is administered as a  
5 pharmaceutically acceptable salt thereof.

8. A method according to claim 1, wherein the compound administered is contained in a  
pharmaceutical composition comprising a pharmaceutically acceptable carrier and a  
pharmaceutically effective amount of the compound.


10 9. A method of providing cardioprotection, or protecting against reperfusion injury, or  
protecting against ischemic injury, in a patient in need thereof comprising administering to  
said patient a pharmaceutically effective amount of a compound having adenosine A1/A2  
agonistic activity, beginning at a time 10 minutes or more before the onset of reperfusion, and  
15 continuing for a period of more than 30 minutes after the onset of reperfusion.

10. A method according to claim 9, wherein the cardioprotection is provided prior to,  
during, or following cardiac surgery.

20 11. A method according to claim 9, wherein the cardioprotection is provided prior to,  
during, or following ischemic attack.

12. A method according to claim 9, wherein the administering of the compound is  
continued for a period of more than 70 minutes after the onset of reperfusion.

25 13. A method according to claim 9, wherein the compound is of the formula



or a pharmaceutically acceptable salt thereof.

- 5      14.      A method according to claim 9, wherein the compound is administered as a  
pharmaceutically acceptable salt thereof.
15.      A method according to claim 9, wherein the compound administered is contained in a  
pharmaceutical composition comprising a pharmaceutically acceptable carrier and a  
10      pharmaceutically effective amount of the compound.